Anti-Cancer Agents

PreclinicalSmall molecule

GGroupe Hospitalier Pitie-Salpetriere

Anti-Cancer Agents is one of 18 small molecule programs targeting Cardiotoxicity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiotoxicityActive, not recruiting

CardiotoxicityPreclinical

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Cardiotoxicity

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

1 2

Avelox

Coreg

4 4

Jardiance

Boehringer Ingelheim

Phase 3

2 5

Farxiga

AstraZeneca

Phase 2

5 6

Adriamycin

Pfizer

Phase 2

3 7

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

1 8

Micardis

Boehringer Ingelheim

Phase 2

1 9

Corlanor

Amgen

Preclinical

2 10

Atacand

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Recruiting

Cardiovascular Complication

NCT03882580

Clinical

Trials by Indication[1]

Cardiovascular Complication1 trial

Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care

Recruiting·GGroupe Hospitalier Pitie-Salpetriere··NCT03882580·5,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Anti-Cancer Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-Cancer Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-Cancer Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Groupe Hospitalier Pitie-Salpetriere company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGroupe Hospitalier Pitie-Salpetriere

Anti-Cancer Agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Cardiovascular Complication1 trial

References

Drug Info

Quick Facts

Related News